• Sara Rimer

    Senior Contributing Editor

    Sara Rimer

    Sara Rimer A journalist for more than three decades, Sara Rimer worked at the Miami Herald, Washington Post and, for 26 years, the New York Times, where she was the New England bureau chief, and a national reporter covering education, aging, immigration, and other social justice issues. Her stories on the death penalty’s inequities were nominated for a Pulitzer Prize and cited in the U.S. Supreme Court’s decision outlawing the execution of people with intellectual disabilities. Her journalism honors include Columbia University’s Meyer Berger award for in-depth human interest reporting. She holds a BA degree in American Studies from the University of Michigan. Profile

    She can be reached at srimer@bu.edu.

Comments & Discussion

Boston University moderates comments to facilitate an informed, substantive, civil conversation. Abusive, profane, self-promotional, misleading, incoherent or off-topic comments will be rejected. Moderators are staffed during regular business hours (EST) and can only accept comments written in English. Statistics or facts must include a citation or a link to the citation.

There are 4 comments on BU Researchers ID Possible Biomarker for Diagnosing CTE during Life

  1. Sara, thank you for the article. This is an interesting discovery. I was surprised to see that CCL11 levels appeared normal in all non-athletes. I am curious to know the age of the control group. I only mention this because a separate 2011 study showed that CCL11 levels increased naturally as part of the aging process (https://www.ncbi.nlm.nih.gov/pubmed/21886162).

    “We identify chemokines–including CCL11 (also known as eotaxin)–the plasma levels of which correlate with reduced neurogenesis in heterochronic parabionts and aged mice, and the levels of which are increased in the plasma and cerebrospinal fluid of healthy ageing humans.”

  2. Can you comment about the relationship between this study and the DETECT-CTE (completed) and DIAGNOSE-CTE (in progress) also at Boston U? DETECT-CTE showed a “tau” blood biomarker (Exosome Science’s TauSome) was 9 times higher in NFL players than in controls. DIAGNOSE-CTE is using both that biomarker and a PET scan using AVID Radiopharmaceutical’s AV-1451 contrast agent (I think that’s the right number). Does Boston now have an opinion about whether CCL11 is a better route than TauSome? When is more DIAGNOSE-CTE data expected?

  3. Is their any warning sighs that you may have it like changes in mood and behavior or a feeling of pressure or bleeding inside your cranium. If so what steps can one take to prevent further Ingery and possibly reverse damage already sustained.

  4. I know athletes or their families rare being asked to donate brains for this research. Is there any program for living volunteers to participate in research for this biomarker?

Post a comment.

Your email address will not be published. Required fields are marked *